Numerous clinical studies have stressed the frequent hormone responsiveness of endometrial carcinoma. Nordqvist (Acta obstet. gynec., scand., 1964, 43, 296) has demonstrated in vitro a direct cancerocidal effect of progesterone.
We have tried to assess the response of endometrial cancer submitted in vitro to various steroids. Pregnenolone (25 jug/ml of medium) markedly enhanced the survival and the cell capacity of mitosis division. Oestradiol 17-fl did not influence survival. On the contrary, progesterone (60-100 ,uLg/ml) and various synthetic progestogens induced constant necrosis without preliminary secretory conversion. This necrosis has not been encountered in non-gynaecological tumours. Progesterone must be in cell contact for several hours to display its necrotizing effect.
We suggest that endometrial cancer cells most often retain steroid binding receptors. The particular effect of pregnenolone might suggest the presence of a steroid metabolizing system affecting cell growth. Radioimmunoassay of casein was carried out using the double antibody solid phase (DASP) method. Incubation was at room temperature for 24 h. This short incubation period was necessitated by the rapid degradation of labelled casein. Thus, 5 days after labelling, the casein no longer reacted with antibody but became nonspecifically bound to proteins and to DASP in the absence of specific antibody.
RADIOIMMUNOASSAY OF CASEIN
The characteristics of the radioimmunoassay for casein were very satisfactory, as indicated by the smallest detectable amount, the precision and the reproducibility as measured by the coefficient of variation within assay.
The immunological reaction was determined by antigenic groups specific to human casein, there being no cross-reaction whatever with bovine casein.
Casein was not usually detectable in the serum of men or normal women who were not lactating. In contrast, all the sera oflactating women contained this natural milk product. In the patients with breast cancer before treatment, casein was found in 72%. In contrast, in benign breast lesions this phosphoprotein was found only rarely. In patients with mammary carcinoma, low blood and urinary levels of androgens have been associated with a poor prognosis. Whether this is due to reduced adrenal synthesis of androgen or altered utilization of androgen precursor is unknown.
We have studied 20 patients with mammary carcinoma and have measured production and metabolic clearance rates of pregnenolone, which is a precursor both of the androgen, dehydroepiandrosterone (DHA), and of cortisol. The DHA: cortisol ratio did not vary between those with early and advanced disease. Of 14 patients with advanced disease treated by endocrine methods 10 responded favourably and 4 poorly. The mean DHA: cortisol ratio in the responders (1.2) was signficantly higher than in the non-responders (0 5).
Pregnenolone metabolic studies may therefore provide a useful guide to predicting hormonal responsiveness in mammary carcinoma. Evidence exists of a relationship between ovarian function and development of breast disease. This study compares levels in premenopausal women with benign and malignant disease with the pattern of serum oestradiol 17/ in normal women. Serum oestradiol 17,B was measured throughout the menstrual cycle in 40 normal women, in 17 with fibroadenosis, in 12 with cystic disease and in 10 with cancer of the breast, by radioimmunoassay (Cameron and Jones, Steroids, 1972, 20, 737) .
SERUM OESTRADIOL 17/ IN NOR-MAL PREMENOPAUSAL WOMEN AND IN PATIENTS WITH BENIGN
Results showed that (1) 36 of the 40 normal premenopausal women exhibited a constant pattern, but concentrations varied with age; (2) oestradiol was low during the follicular phase of the normal cycle (35 3 + 4.4 pg/ml), rose to sharp pre-ovulation peak (192-9 ± 12-7 pg/ml) and plateaued during the luteal phase (67.3 ± 1P5 pg/ml); (3) patients with fibroadenosis showed a concentration pattern not significantly different from normal; (4) in patients with cystic disease, concentrations were significantly higher during the luteal phase; (5) 
